Market Place
Sourcing Support
Elevar Announces FDA Acceptance Of Rivoceranib For HCC Treatment
21 Oct 2024 //
GLOBENEWSWIRE
Elevar Resubmits NDA For Camrelizumab Plus Rivoceranib In HCC
23 Sep 2024 //
GLOBENEWSWIRE
Elevar Therapeutics Gets EU Orphan Drug Designation For HCC Therapy
01 Aug 2024 //
GLOBENEWSWIRE
FDA rejects Elevar, Hengrui`s PD-1 combo
18 May 2024 //
FIERCE PGARMA
HLB fails to win US FDA`s approval for Rivoceranib liver cancer drug
17 May 2024 //
KOREATIMES
Jiangsu Hengrui and Elevar Therapeutics Announce Agreement for Camrelizumab
17 Oct 2023 //
GLOBENEWSWIRE
Elevar to Host August 10 Virtual KOL Event on Phase 3 Study of Rivoceranib
03 Aug 2023 //
GLOBENEWSWIRE
Elevar Announces Acceptance for Filing of NDA for Rivoceranib with Camrelizumab
17 Jul 2023 //
GLOBENEWSWIRE
Elevar Submits NDA to FDA for Combination of Rivoceranib and Camrelizumab
17 May 2023 //
GLOBENEWSWIRE
Elevar to Present Poster at AACR Demonstrating Rivoceranib as Poten for VEGFR-2
16 Mar 2023 //
GLOBENEWSWIRE
Avenue Therapeutics Announces Closing of $12 M Underwritten PO
11 Oct 2022 //
GLOBENEWSWIRE
Elevar Announces Positive Pre-NDA Meeting for Rivoceranib Camrelizumab
11 Oct 2022 //
GLOBENEWSWIRE
Camrelizumab with Rivoceranib vs. Sorafenib, a Joint Program with Elevar
11 Sep 2022 //
PRNEWSWIRE
HLB’s anticancer drug candidate shows longest survival against liver cancer
08 Sep 2022 //
KOREAHERALD
Elevar Announces Camrelizumab Plus Rivoceranib Significantly Prolonged
07 Sep 2022 //
GLOBENEWSWIRE
Elevar Therapeutics Shares Results of PII Rivoceranib Trial
06 Jun 2022 //
GLOBENEWSWIRE
Hengrui Pharma Announces Frontline Camrelizumab in Combination with Rivoceranib
13 May 2022 //
PRESS RELEASE
Another Chinese PD-1 cancer med eyes FDA filing in liver cancer
12 May 2022 //
FIERCEPHARMA
HLB’s liver cancer treatment awarded Orphan Drug Status by FDA
08 Nov 2021 //
PHARMAFILE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.